Tumors with BRAF V600E alteration are enriched with consensus molecular subtype 1, which is characterized by rich immune infiltration in the tumor microenvironment.38,39 In our analysis, 2 of the 4 patients with BRAF V600E alteration had a partial response as the best response to PD-1/PD-L1 targeting. The gene discussed is CD274; the disease is neoplasm.